Day: August 16, 2021

Firm Capital Property Trust Announces Strong Second Quarter Results and $8.15/Unit NAV

Written by Customer Service on August 16, 2021. Posted in Earnings Releases And Operating Results.

TORONTO, Aug. 16, 2021 (GLOBE NEWSWIRE) — Firm Capital Property Trust (“FCPT” or the “Trust”), (TSXV: FCD.UN) is pleased to report its financial results for the period ended June 30, 2021. PROPERTY PORTFOLIO HIGHLIGHTS The portfolio consists of 63 commercial properties with a total gross leasable area (“GLA”) of 2,266,676 square feet, four multi-residential complexes comprised of 464 units and one Manufactured Home Community comprised of 181 units. The portfolio is well diversified and defensive in terms of geographies and property asset types, with 60% of NOI comprised of grocery anchored retail followed by industrial at 22% of NOI. TENANT DIVERSIFICATION The portfolio is well diversified by tenant profile with no tenant currently accounting for more than 11.6% of total net rent. Further, the top 10 tenants are comprised of...

Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Written by Customer Service on August 16, 2021. Posted in Earnings Releases And Operating Results.

-Closed Underwritten Public Offering of Common Stock and Warrants Resulting in Gross Proceeds of $34.5 Million -Expected to Initiate Pivotal Phase 3 Clinical Trial in Schizophrenia in Q4’21 -$35.8 Million in Cash as of June 30, 2021 CUPERTINO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today reported financial results for the second quarter of 2021 and summarized recent business highlights. “We believe the recent closing of our successful public offering, resulting in gross proceeds of $34.5 million, supported by institutional investors, provides the...

Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Written by Customer Service on August 16, 2021. Posted in Earnings Releases And Operating Results.

TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021 Preparations On Track for Potential TRUDHESA Launch in the Fourth Quarter of 2021 Increased Cash Position and Extended Runway through 2022 Following $50 Million Debt Facility Agreement with Oxford Finance LLC and Silicon Valley Bank Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, Aug. 16, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma (NASDAQ: IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS, today reported financial results for the second quarter ended June 30, 2021 and...

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Written by Customer Service on August 16, 2021. Posted in Earnings Releases And Operating Results.

Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy treatment of MDD PRAX-114 to advance in Phase 2b study in women with menopausal and mood symptoms PRAX-944 Phase 2b study for treatment of essential tremor to initiate in 3Q21; Phase 2a topline results expected by the end of 2021 PRAX-562 Phase 1 healthy volunteer study completed with dose up to 150 mg and favorable safety profile Cash and investments of $339.2 million as of June 30, 2021 supports runway into 2Q23 CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous...

Net Element Reports Second Quarter 2021 Financial Results

Written by Customer Service on August 16, 2021. Posted in Earnings Releases And Operating Results.

MIAMI, Aug. 16, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multichannel environment including point-of-sale (“POS”), e-commerce and mobile devices, today reports its financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Financial ResultsNet revenue increased to $33.3 million, as compared to $13.7 million for the same comparable period in 2020. North American Transactions Solutions revenue increased to $32 million, as compared to $13 million for the same comparable quarter in 2020. International Transaction Solutions revenue increased to $1.3 million, as compared to $0.74 million for the same comparable quarter in 2020. Operating...

Delta 9 Reports Financials for Q2 2021

Written by Customer Service on August 16, 2021. Posted in Earnings Releases And Operating Results.

WINNIPEG, Manitoba, Aug. 16, 2021 (GLOBE NEWSWIRE) — DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the “Company”), is pleased to announce financial and operating results for the three-month and six-month period ending June 30, 2021. Financial Highlights for the three-month period ending June 30, 2021Net revenue of $16.75 million for the second quarter of 2021, an increase of 29%, from $13.0 million for the same quarter last year.Sequential net revenue increased 27% versus $13.2 million for the three-month period ending March 31, 2021Gross profit of $4.9 million for the second quarter of 2021, an increase of 25%, from $3.95 million for the same quarter last year. Net loss from operations of $(0.8) million for the second quarter of 2021 versus a loss from operations of $(0.2) million for the same quarter last...

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

Written by Customer Service on August 16, 2021. Posted in Earnings Releases And Operating Results.

Company ends Q2 ’21 with cash and cash equivalents of $212.2 million Recent appointments to Company leadership strongly position Ovid to advance current and future neuroscience programs Ovid is actively pursuing business development opportunities to complement its neuroscience pipelineNEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today reported financial results for the quarter ended June 30, 2021. The Company also provided an overview of recently announced leadership appointments that will guide and execute its strategy. “The second quarter was extremely productive for Ovid. We appointed experts with deep neuroscience development and investment acumen to our board...

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

Written by Customer Service on August 16, 2021. Posted in Earnings Releases And Operating Results.

WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced its financial results for the quarter ended June 30, 2021, and recent events. “It has been an exciting quarter for Aerovate as we received scientific advice from the EMA, received regulatory guidance from the FDA at our end-of-Phase 1 meeting, and we expect to initiate enrollment this year in the Phase 2b portion of our Phase 2b/3 trial of AV-101 in PAH,” said Timothy Noyes, chief executive officer of Aerovate. “We are also pleased with investor confidence in Aerovate to support our IPO and provide sufficient capital which we believe will fund Aerovate into the second...

SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Written by Customer Service on August 16, 2021. Posted in Earnings Releases And Operating Results.

BREXAFEMME® (ibrexafungerp tablets), the first novel antifungal class drug approved by the U.S. Food and Drug Administration (FDA) in more than 20 years, qualifies for 10 years of regulatory exclusivity and has 14 years of U.S. patent protection U.S. commercial launch of BREXAFEMME began in August; the treatment is now available at pharmacies and payer discussions are rapidly progressingClinical development of ibrexafungerp continues to progress with the completion of enrollment in the Phase 3 CANDLE study in recurrent vulvovaginal candidiasis and ongoing Phase 1 dosing of a liposomal IV formulationFurther strengthened balance sheet and projected cash runway into 2023 by accessing a $10 million tranche of Hercules/SVB debt that became available following BREXAFEMME FDA approvalJERSEY CITY, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE)...

Badger Infrastructure Solutions Ltd. August 2021 Cash Dividend

Written by Customer Service on August 16, 2021. Posted in Dividend Reports And Estimates.

CALGARY, Alberta, Aug. 16, 2021 (GLOBE NEWSWIRE) — Badger Infrastructure Solutions Ltd. (“Badger”) is pleased to announce its August 2021 cash dividend. August 2021 Cash DividendBadger today announced that the directors of Badger declared a cash dividend for the month of August 2021 of $0.0525 per share, which equates to $0.63 per share on an annualized basis. Payment will be made on or about September 15, 2021, to shareholders of record on August 31, 2021. Badger expects that the dividend will be an “eligible dividend” for Canadian income tax purposes and thus qualify for the enhanced gross-up and tax credit regime for certain shareholders. About Badger Infrastructure Solutions Ltd.Badger Infrastructure Solutions Ltd. (TSX:BDGI) is North America’s largest provider of non-destructive excavating services. Badger works for contractors...

Day: August 16, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice